Ana Domínguez, Guillermo Pacho, Lisa Bowers, Fridolin Wild, Sarah Alcock, Giuseppe Chiazzese, Mariella Farella, Marco Arrigo, David Ross, Rita Treacy, Darya Yegorina, Eleni Mangina, Stefano Masneri
Dataset of user interactions across four large pilots on the use of augmented reality in learning experiences
Scientific data
targeting mucosal immunity gut known provide antigen processing avoiding excessive unnecessary inflammation tested way modulate covid19 severity randomized openlabel trial 204 adults hospitalized noncritical covid19 received 14 days addition standard care soc degalactosylated bovine glycoproteins formulations either maf capsules maf group capsules group soc control group median recovery time patients require supplemental oxygen 6 days study groups compared 9 days control maf vs control p 0020 vs control p 0004 greater reduction mortality seen maf group compared control day 14 83 vs 16 p 0121 day 29 153 vs 32 p 0020 similarly group day 14 83 vs 29 p 0276 day 29 153 vs 29 p 0017 proportion baseline absolute lymphocyte count alc lower 08 109l 1363 206 1769 246 1872 250 patients maf control group respectively day 29 mortality among lymphopenic patients three times higher intenttotreat population 21 vs 7 consisted subgroups 213 15 217 12 618 33 patients decreased mortality study subgroups correlated greater alc restoration 08 109l level seen day 14 91 1112 875 1416 survivors maf subgroups respectively compared 533 815 survivors control subgroup incidences alc decrease baseline level day 14 occurred 254 patients maf group 290 patients group compared 458 control alc depletion 50 baseline level consisted 79 58 153 cases groups respectively study showed study agents prevented alc depletion accelerated restoration believed one mechanisms improved crucial clinical outcomes hospitalized covid19 patients trial registered trial start clinicaltrialsgov nct04762628 registered 21022021 httpswww govct2shownct04762628